Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Parasitology ; 148(2): 227-233, 2021 02.
Article in English | MEDLINE | ID: mdl-32729438

ABSTRACT

A subcommittee of the Hawaii Governor's Joint Task Force on Rat Lungworm Disease developed preliminary guidelines for the diagnosis and treatment of neuroangiostrongyliasis (NAS) in 2018 (Guidelines, 2018). This paper reviews the main points of those guidelines and provides updates in areas where our understanding of the disease has increased. The diagnosis of NAS is described, including confirmation of infection by real-time polymerase chain reaction (RTi-PCR) to detect parasite DNA in the central nervous system (CNS). The treatment literature is reviewed with recommendations for the use of corticosteroids and the anthelminthic drug albendazole. Long-term sequelae of NAS are discussed and recommendations for future research are proposed.


Subject(s)
Angiostrongylus cantonensis/physiology , Strongylida Infections , Adrenal Cortex Hormones/administration & dosage , Albendazole/administration & dosage , Animals , Anthelmintics/administration & dosage , Hawaii , Humans , Strongylida Infections/diagnosis , Strongylida Infections/drug therapy
2.
Hawaii J Health Soc Welf ; 79(12): 353-357, 2020 12 01.
Article in English | MEDLINE | ID: mdl-33313517

ABSTRACT

Angiostrongylus cantonensis is a metastrongylid lungworm of rats with a global distribution and the cause of neuroangiostrongyliasis in humans. In Hawai'i, neuroangiostrongyliasis cases have occurred sporadically since 1960; however, in 2001, the number of cases on Maui and Hawai'i Island began to increase significantly. Since most human treatment trials have been conducted in Thailand, where the disease is usually mild, there is a need to develop treatment protocols for Hawai'i, where there is a broader disease spectrum. In 2018, preliminary guidelines for the diagnosis and treatment of neuroangiostrongyliasis were developed for Hawai'i's physicians. This article summarizes those guidelines and provides additional recommendations for individuals who recently ingested an infected intermediate host.


Subject(s)
Angiostrongylus cantonensis , Physicians , Animals , Hawaii/epidemiology , Humans , Rats , Thailand
3.
Pharmacy (Basel) ; 7(3)2019 Jul 17.
Article in English | MEDLINE | ID: mdl-31319528

ABSTRACT

Antimicrobials in the penicillin class are first line treatments for several infectious diseases in the pediatric and adult population today. In the United States, patients commonly report having a penicillin allergy, with penicillin being the most frequent beta-lactam allergy. However, very few patients experience a clinically significant immune-mediated allergic reaction to penicillin. If a true penicillin allergy exists, cross-reactivity to other beta-lactam antimicrobials may occur. Mislabeling patients with penicillin allergy can lead to a higher utilization of second line antimicrobial agents, potentially increasing costs and resistance due to a larger spectrum of activity. Pharmacists play an essential role in inquiring about patient specific reactions to presumed medication allergies and developing a further assessment plan, if needed, to determine if the medication allergy is real.

4.
Hawaii J Med Public Health ; 76(2): 59-64, 2017 02.
Article in English | MEDLINE | ID: mdl-28210531

ABSTRACT

Clostridium difficile remains a major source of nosocomial infections and associated diarrhea. More recently, community-acquired cases are on the rise creating a concern for a serious public health threat. Appropriate infection control precautions as well as prevention and optimal management may help to avoid detrimental outbreaks. A key step is utilizing laboratory testing for quick and accurate diagnosis of potential cases. This overview article describes Clostridium difficile infection control and prevention methods and updates the most recent management strategies including a focus on the utilization and interpretation of laboratory diagnostic testing and appropriate treatment.


Subject(s)
Clostridioides difficile/pathogenicity , Clostridium Infections , Cross Infection , Clostridium Infections/diagnosis , Clostridium Infections/drug therapy , Clostridium Infections/prevention & control , Cross Infection/diagnosis , Cross Infection/drug therapy , Cross Infection/prevention & control , Hawaii , Humans
5.
Curr Cardiol Rev ; 13(4): 274-282, 2017.
Article in English | MEDLINE | ID: mdl-28782494

ABSTRACT

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been gaining major attention recently after the emergence of data showing the promising role of these proteins in lipid homeostasis and atherosclerosis process, glucose and blood pressure regulation. MATERIALS AND METHODS: PubMed, EMBASE, Scholar and Scopus databases were searched to identify randomized controlled trials, observational studies, in-vitro trials and reviews about the role of PCSK9 in cardiovascular homeostasis. RESULTS: PCSK9 was found to have major impact on lipid homeostasis and inflammatory process through regulation of low-density lipoprotein receptors. Furthermore, inflammation was found to stimulate the expression of PCSK9 in various cells. As for glomerular proteinuria, a positive correlation was determined between PCSK9 levels and the degree of proteinuria. Hypertension, a major cardiovascular risk factor, is likely affected by PCSK9 levels through their role on epithelial sodium channel (ENaC) surface expression. Likewise, some studies show that PCSK9 is associated with higher fasting blood glucose and plasma insulin, demonstrating a potential role of PCSK9 in glucose homeostasis. The role of PCSK9 in cardiovascular homeostasis is one that is still not completely unraveled. CONCLUSION: Studies have clearly shown the implication of PCSK9 in the cardiovascular risk factors: the higher the PCSK9 levels, the higher the risk of atherosclerosis, fasting plasma glucose and insulin resistance. Inhibiting PCSK9 may therefore theoretically prove to present great benefits in diabetic patients with high cardiovascular risk.


Subject(s)
Cardiovascular Diseases/genetics , Gene Expression Regulation , Homeostasis/physiology , Proprotein Convertase 9/genetics , Cardiovascular Diseases/enzymology , Humans , Proprotein Convertase 9/biosynthesis , Receptors, LDL
SELECTION OF CITATIONS
SEARCH DETAIL